REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202, a differentiated ...

US gene therapy company Regenxbio has reported new, positive interim data from two additional patients in the Phase I/II ...

Regenxbio shares were 13% higher at $8.79, after the company said it saw positive interim data from two new patients in a Phase I/II trial of RGX-202, a differentiated investigational gene therapy for ...

"RGX-202 is the only next generation gene therapy for Duchenne in a pivotal phase trial. The new data from the age 1-3 cohort builds on the favorable safety and efficacy profile seen in ages 4 and ...

(RTTNews) - REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of RGX-202, a differentiated investigational ...

RGX-202, a DMD gene therapy, has been well tolerated in an ongoing clinical trial and improved motor function for DMD boys, per interim data.

Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...

REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

ROCKVILLE, Md. - REGENXBIO Inc. (NASDAQ:RGNX) has shared new interim data from its ongoing Phase I/II AFFINITY DUCHENNE® trial, evaluating RGX-202, an investigational gene therapy for Duchenne ...

Q4 2024 Earnings Call Transcript March 13, 2025 REGENXBIO Inc. beats earnings expectations. Reported EPS is $-1.01, ...